Gapping up
In reaction to strong earnings/guidance:
- OIS +31.3%, AX +20.4%, MTDR +18.1%, AR +16.9%, UCTT +12.6%, MTSI +11.1%, TPX +10.1%, FLWS +9.5%, WHD +9.1%, SIX +8.8%, FB +8.4%, TSLA +7.7%, MSA +7.4%, NGVT +6.3%, NOK +6.3%, SPB +6.1%, NOW +5.8%, TWTR +4.9%, FICO +4.7%, AGIO +4.5%, AGI +4.2%, CONE +4.1%, VRTX +3.6%, JBT +3.4%, HCC +3.2%, AGNC +3.2%, MPW +3.1%, HBI +3.1%, NLY +3%, SNP +2.9%, MTOR +2.9%, AVTR +2.7%, COP +2.7%, ICE +2.6%, PTC +2.5%, ONDK +2.5%, PEGA +2.4%, AIMC +2.4%, BAX +2.4%, LKQ +2.3%, GIL +2.2%, MSFT +2%, TXT +1.9%, AM +1.8%, RFP +1.7%, KHC +1.7%, MOBL +1.6%, MO +1.6%, BMRN +1.5%, SHI +1.5%, CMCSA +1.5%, CI +1.4%, ETN +1.4%, QCOM +1.3%, AAL +1.3%, PS +1.2%, INSM +1.2%, ORAN +1.1%, TFX +1.1%, WLTW +1%
Other news:
- MRKR +22.9% (granted FDA Orphan Drug designation to MT-401)
- HOLX +9.9% (to launch new Aptima molecular assay to detect the SARS-CoV-2 virus)
- PSTI +8.8% (receives €50 million of financing from European Investment Bank)
- CHS +7.9% (names new CEO; also announces restructure to get leaner)
- SIGA +7.9% (announces BARDA exercise of contract options valued at approx. $101.3 mln)
- AZN +4.7% (to collaborate with Oxford University for COVID-19 vaccine)
- FTAI +4.7% (Fortress Transportation and Infrastructure announces agreement with Air France for the purchase and leaseback of sixteen aircraft) MESO +4.7% (begins enrollment in Phase 2/3 trial of remestemcel-L in 300 patients with COVID-19 acute ARDS)
- BCEL +4.2% (announces collaboration on novel antibody treatment for COVID-19)
- UNIT +2.7% (Uniti Fiber comments on connectivity initiatives)
- AMC +2.1% (files to delay its 10-K and 10-Q)
- GSK +1.8% (FDA approval of Zejula as monotherapy maintenance treatment)
- BA +1.8% (rising despite S&P cutting rating on Boeing to BBB- from BBB; watch negative)
Analyst comments:
- IFRX +13.3% (upgraded to Outperform from Mkt Perform at Raymond James)
- LUV +2.5% (upgraded to Buy from Hold at Stifel)
- MERC +2% (upgraded to Outperform from Neutral at Credit Suisse)